LivaNova (NASDAQ:LIVN) Hits New 52-Week High Following Better-Than-Expected Earnings

Shares of LivaNova PLC (NASDAQ:LIVN – Get Free Report) reached a new 52-week high on Wednesday following a better than expected earnings announcement. The company traded as high as $90.00 and last traded at $90.6750, with a volume of 14,495 shares changing hands. The stock had previously closed at $79.90.

The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17. The company had revenue of $393.15 million for the quarter, compared to analysts’ expectations of $381.13 million. LivaNova had a net margin of 13.01% and a return on equity of 16.10%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

  • Positive Sentiment: Q3 results topped expectations. LivaNova reported adjusted earnings of $1.23 per share, ahead of estimates of about $1.03–$1.06, and revenue of $393.15 million versus roughly $381 million expected. Revenue rose 9.9% year over year. LivaNova Surpasses Q3 Earnings and Revenue Estimates
  • Positive Sentiment: 2026 outlook improved. The company forecast revenue growth of 9%–10% and raised its full-year EPS guidance to $4.40–$4.50, signaling confidence in continued growth. LivaNova forecasts 2026 growth and raises EPS guidance
  • Positive Sentiment: Analysts raised their targets. Needham lifted its target to $112 from $93 and maintained a Buy rating; Baird raised its target to $111 from $95 and kept an Outperform rating. The revisions reflect more favorable expectations after the results and guidance update. Needham raises LivaNova price target
  • Neutral Sentiment: OSA neuromodulation is a potential longer-term opportunity. Coverage highlighted LivaNova’s interest in entering this market, but the articles provided no details on timing, investment, or expected commercial impact. LivaNova eyes OSA neuromodulation entry

Wall Street Analyst Weigh In

LIVN has been the subject of a number of research analyst reports. Weiss Ratings raised LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, October 27th. Mizuho set a $115.00 price target on LivaNova in a report on Wednesday. Robert W. Baird raised their price target on LivaNova from $95.00 to $111.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC lifted their price objective on LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Zacks Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $99.56.

View Our Latest Stock Report on LivaNova

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director owned 4,434 shares of the company’s stock, valued at $345,896.34. This trade represents a 44.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the sale, the director directly owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 7,450 shares of company stock valued at $591,839. Company insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LIVN. AlphaCore Capital LLC acquired a new position in LivaNova during the third quarter worth $308,000. Hohimer Wealth Management LLC grew its position in LivaNova by 5.4% in the third quarter. Hohimer Wealth Management LLC now owns 4,277 shares of the company’s stock valued at $327,000 after purchasing an additional 219 shares in the last quarter. Alamar Capital Management LLC bought a new position in LivaNova in the third quarter valued at $1,814,000. Covestor Ltd increased its stake in LivaNova by 135.1% in the 3rd quarter. Covestor Ltd now owns 1,300 shares of the company’s stock valued at $99,000 after buying an additional 747 shares during the last quarter. Finally, Vise Technologies Inc. increased its stake in LivaNova by 40.3% in the 3rd quarter. Vise Technologies Inc. now owns 3,915 shares of the company’s stock valued at $299,000 after buying an additional 1,124 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Down 3.2%

The firm’s 50 day simple moving average is $79.08 and its 200-day simple moving average is $73.40. The company has a current ratio of 1.46, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $5.02 billion, a price-to-earnings ratio of 25.81 and a beta of 0.91.

LivaNova Company Profile

(Get Free Report)

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.

Featured Stories

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.